FMR LLC boosted its holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 28.1% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 6,341,391 shares of the company's stock after purchasing an additional 1,391,167 shares during the period. FMR LLC owned about 9.92% of MoonLake Immunotherapeutics worth $343,386,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of MoonLake Immunotherapeutics by 96.4% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 35,814 shares of the company's stock valued at $1,806,000 after purchasing an additional 17,580 shares in the last quarter. Barclays PLC raised its holdings in MoonLake Immunotherapeutics by 1,269.2% in the third quarter. Barclays PLC now owns 5,641 shares of the company's stock valued at $283,000 after acquiring an additional 5,229 shares in the last quarter. State Street Corp raised its holdings in MoonLake Immunotherapeutics by 96.2% in the third quarter. State Street Corp now owns 87,637 shares of the company's stock valued at $4,419,000 after acquiring an additional 42,980 shares in the last quarter. Congress Asset Management Co. grew its holdings in MoonLake Immunotherapeutics by 9.5% during the 4th quarter. Congress Asset Management Co. now owns 72,993 shares of the company's stock worth $3,953,000 after acquiring an additional 6,352 shares in the last quarter. Finally, KLP Kapitalforvaltning AS bought a new stake in shares of MoonLake Immunotherapeutics in the 4th quarter worth about $244,000. Hedge funds and other institutional investors own 93.85% of the company's stock.
Analyst Ratings Changes
Several equities analysts have recently commented on the stock. Royal Bank of Canada started coverage on shares of MoonLake Immunotherapeutics in a research report on Tuesday, March 18th. They set an "outperform" rating and a $67.00 price target on the stock. HC Wainwright reiterated a "buy" rating and issued a $100.00 price target on shares of MoonLake Immunotherapeutics in a report on Thursday, February 27th. The Goldman Sachs Group reduced their price objective on MoonLake Immunotherapeutics from $82.00 to $73.00 and set a "buy" rating on the stock in a research note on Thursday, February 27th. Finally, Needham & Company LLC increased their target price on shares of MoonLake Immunotherapeutics from $62.00 to $66.00 and gave the stock a "buy" rating in a report on Thursday, February 27th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $80.50.
Read Our Latest Stock Analysis on MoonLake Immunotherapeutics
MoonLake Immunotherapeutics Trading Up 3.1 %
NASDAQ:MLTX traded up $1.10 during mid-day trading on Tuesday, hitting $36.85. The stock had a trading volume of 172,673 shares, compared to its average volume of 344,547. The company has a 50 day simple moving average of $39.63 and a 200-day simple moving average of $46.34. The stock has a market capitalization of $2.36 billion, a price-to-earnings ratio of -28.47 and a beta of 1.32. MoonLake Immunotherapeutics has a 52 week low of $31.42 and a 52 week high of $58.26.
MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.09). As a group, equities research analysts anticipate that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current year.
MoonLake Immunotherapeutics Company Profile
(
Free Report)
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
Featured Articles
Before you consider MoonLake Immunotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MoonLake Immunotherapeutics wasn't on the list.
While MoonLake Immunotherapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
